Input | Base case | Scenario analysis |
---|---|---|
Vaccination target population | Paediatric population vaccinated at birth (0–100% coverage) | Paediatric population vaccinated at birth (70–100% coverage) |
Optimization time horizon | 10 years | 5 years |
Vaccine efficacy | 73% | 50%, 80% |
Time horizon | 10 years | 5 years |
Inpatient costs | - $266 DF inpatient direct medical costs [74] - $566.43 DHF inpatient direct medical costs [70] - $72.77 inpatient direct non-medical costs [70] - $54.59 inpatient indirect costs [70] | Unit cost profiles from Fitzpatrick et al. [59] - $141.55 hospital bed day, primary - $169.24 hospital bed day, specialist |
Outpatient costs | - $141.61 outpatient direct medical costs [70] - $82.20 outpatient direct non-medical costs [70] - $13.65 outpatient indirect costs [70] | Unit cost profile from Fitzpatrick et al. [59] - $18.29 ambulatory clinic visit |
Cost of ‘un-reported’ cases | $12.12 for clinic visit [73] | N/ A |
Vaccine price per course | $40 plus $4 vaccine administration costs | $20 plus $4 vaccine administration costs; $60 plus $4 vaccine administration costs |
Wolbachia | Wolbachia cost per dengue case averted of $1 (i.e. cost of release per person covered of $4.45) | Wolbachia cost per person covered of $1 [75,76,77]; Wolbachia cost per person covered of $15.05 [75,76,77] (adjusted to 2013 prices [78]) |